Biosplice Therapeutics
SAN FRANCISCO, CA · Founded 2021 · CIK 0001848940 · Biotech · Private
CLK and DYRK kinase inhibitors that modulate RNA splicing
biosplice.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- —
- 2 Form D · Aug 2022
- 49 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 21 granted · 19 pending
- Sector median: 2
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1881 | Cardiol Therapeutics Inc. | — | $6.0M |
| 1882 | IMMUNO NANO MED, INC | — | — |
| 1883 | MycoRx LLC | — | $600K |
| 1884 | Biosplice Therapeutics | — | — |
| 1885 | Krystal Biotech, Inc. | — | $11M |
| 1886 | SANOSTEM GLOBAL, LLC | — | $3.5M |
| 1887 | Protocol 46 Inc. | — | $410K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Darrin BeaupreExecutive Officer
- Scott BulcaoExecutive Officer
- Troy CoxDirector
- Joy GhoshDirector
- Susannah GrayDirector
- Erich HorsleyExecutive Officer
- Osman KibarDirector · Executive Officer
- Karen McGinnisDirector
- Arman OrucExecutive Officer
- Kyle RasbachDirector
- Gur RoshwalbDirector
- Cevdet SamikogluDirector · Executive Officer
- Yusuf YaziciExecutive Officer
Patents
- Combination Therapy With Clk/dyrk Inhibitors And BCL2 Inhibitors To Treat Leukemiagranted
- Indazole Inhibitors Of The Wnt Signal Pathway And Therapeutic Uses Thereofapplication
- ISOQUINOLIN-3-YL Carboxamides And Preparation And Use Thereofapplication
- 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES And Preparation And Uses Thereofapplication
- 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES And Preparation And Uses Thereofapplication
- PYRROLO[2,1-F][1,2,4]TRIAZINES And Preparation And Uses Thereofapplication
- 7H-PYRROLO[2,3-D]PYRIMIDINES And Preparation And Uses Thereofapplication
- ISOQUINOLIN-3-YL Carboxamides And Preparation And Use Thereofgranted
- Process For Preparing N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDEapplication
- PYRROLO[2,1-F][1,2,4]TRIAZINES And Preparation And Uses Thereofgranted
- 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES And Preparation And Uses Thereofapplication
- Process For Preparing N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDEgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.